Breast malignant, males, children
Breast cancer
Prognostic factors - Multigene products

Author: Monika Roychowdhury, M.D. (see Authors page)

Revised: 20 October 2016, last major update March 2012

Copyright: (c) 2002-2016,, Inc.

PubMed Search: Multigene products [title]

Table of Contents
Definition / general
Cite this page: Prognostic factors - Multigene products. website. Accessed June 24th, 2018.
Definition / general

  • Prognostic test for women under age of 61 years with lymph node-negative breast cancer (ER positive or negative)
  • Requires freshly prepared tissue collected in RNA preservative solution
  • The assay is comprised of 70 genes focused on proliferation, invasion, metastasis, stromal integrity and angiogenesis

  • Uses five immunohistochemical markers (p53, HTF9C, CEACAM5, NDRG1 and SLC7A5) on paraffin fixed tissue to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions
  • Increased scores were significantly associated with reduced survival in ER+ positive breast cancer (Breast Cancer Res 2010;12:R47)

Oncotype DX™
  • First available in January 2004
  • Measures changes in 21 genes on paraffin fixed tissue to predict likelihood of disease recurrence and which patients are most likely to respond to chemotherapy (Breast Cancer Res 2006;8:R25)
  • Recurrence score is used for some patients with ER+, node negative breast cancer
  • Recurrence score is associated with real world decision changes (Am J Surg 2008;196:527, J Surg Oncol 2009;99:319); use is increasing, reduces adjuvant chemotherapy utilization (Ann Surg Oncol 2011;18:3399)